Amgen, Inc. (AMGN) Shares Sold by Public Employees Retirement System of Ohio
Public Employees Retirement System of Ohio lowered its holdings in Amgen, Inc. (NASDAQ:AMGN) by 3.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 517,405 shares of the medical research company’s stock after selling 18,032 shares during the period. Public Employees Retirement System of Ohio owned approximately 0.07% of Amgen worth $89,113,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in AMGN. TrimTabs Asset Management LLC raised its holdings in shares of Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after acquiring an additional 288 shares in the last quarter. American Beacon Advisors Inc. purchased a new stake in shares of Amgen during the first quarter worth $106,000. Jackson Grant Investment Advisers Inc. raised its holdings in shares of Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after acquiring an additional 5 shares in the last quarter. Omnia Family Wealth LLC raised its holdings in shares of Amgen by 25.3% during the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after acquiring an additional 147 shares in the last quarter. Finally, Grove Bank & Trust raised its holdings in shares of Amgen by 87.4% during the second quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock worth $126,000 after acquiring an additional 341 shares in the last quarter. Institutional investors own 78.62% of the company’s stock.
Several brokerages recently issued reports on AMGN. Royal Bank of Canada began coverage on Amgen in a report on Thursday, September 14th. They set a “sector perform” rating and a $192.00 price objective for the company. Bank of America increased their price objective on Amgen to $210.00 and gave the stock a “buy” rating in a report on Thursday, October 5th. Oppenheimer reiterated a “buy” rating and set a $203.00 price objective on shares of Amgen in a report on Friday, October 6th. Mizuho reiterated a “buy” rating and set a $198.00 price objective on shares of Amgen in a report on Friday, October 6th. Finally, Morgan Stanley reissued an “overweight” rating and set a $196.00 target price (up from $189.00) on shares of Amgen in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the stock. Amgen has a consensus rating of “Hold” and an average price target of $190.22.
In other news, Director Carbonnel Francois De sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $171.58, for a total value of $261,659.50. Following the completion of the sale, the executive vice president now directly owns 57,631 shares in the company, valued at $9,888,326.98. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,575 shares of company stock worth $1,509,339. 0.19% of the stock is currently owned by company insiders.
Amgen, Inc. (AMGN) opened at $176.26 on Wednesday. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. The company has a market cap of $128,362.77, a price-to-earnings ratio of 14.06, a price-to-earnings-growth ratio of 2.56 and a beta of 1.36. Amgen, Inc. has a 1 year low of $145.12 and a 1 year high of $191.10.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The firm’s revenue was down .7% compared to the same quarter last year. During the same period last year, the business posted $3.02 earnings per share. equities analysts anticipate that Amgen, Inc. will post 12.66 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a $1.32 dividend. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 3.00%. Amgen’s dividend payout ratio (DPR) is currently 41.63%.
Amgen announced that its Board of Directors has initiated a stock buyback plan on Wednesday, October 25th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its stock is undervalued.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with Analyst Ratings Network's FREE daily email newsletter.